TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12616206

Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Partial turbinectomy (PT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Radiofrequency tissue ablation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Rhinomanometric measurements
Number of subjects: 135
Study: 10675166

Group type: EXPERIMENTAL
Intervention: Pelvic-floor re-education programme for up to 1 year
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo therapy (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pelvic-floor re-education
Number of subjects: 102
Study: 8814201

Group type: EXPERIMENTAL
Intervention: Fish oil (35 mg 20:5(n‐3) + 22:6(n‐3)/(kg body weight.d))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (35 mg 18:3(n‐3)/(kg body weight.d))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Olive oil (35 mg 18:1/(kg body weight.d))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All oil treatments
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fish oil and olive oil supplementation
Number of subjects: 26
Study: 1728671

Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Duplex scanning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Angioscopy
Number of subjects: 20
Study: 6368906

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions plus antibiotic therapy (IFCL & CFCL group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions plus antibiotic therapy (FL group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antibiotic therapy alone (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions plus antibiotic therapy (all transfused patients)
Number of subjects: 75
Study: 31509182

Group type: EXPERIMENTAL
Intervention: 200/50 mg dispersible levodopa/benserazide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30071909

Group type: EXPERIMENTAL
Intervention: Web-based intervention (GET.ON M.E.D.)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Active control group receiving web-based psychoeducation
Number of subjects: 260
Study: 26052813

Group type: EXPERIMENTAL
Intervention: Combination therapy of daily topical antioxidant hydrogel plus excimer light (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Excimer light alone (Group B)
Number of subjects: 30
Study: 24774442

Group type: EXPERIMENTAL
Intervention: Intravaginal prasterone (DHEA) 0, 3.25 mg, 6.5 mg or 13 mg daily for 12 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Intravaginal prasterone (DHEA) in the MSD+ group
Number of subjects: 215

Group type: COMPARATOR
Intervention: Intravaginal prasterone (DHEA) in the MSD- group
Number of subjects: 215
Study: 22815298

Group type: EXPERIMENTAL
Intervention: CLP (closed-loop control plus 30-μg premeal injections of pramlintide)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CL (closed-loop control alone)
Number of subjects: 8
Study: 20051276

Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (5 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (20 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (80 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AMA1-C1 vaccine (5 microg and 20 microg)
Number of subjects: 24
Study: 18173921

Group type: EXPERIMENTAL
Intervention: Carriage of TNFRII R variant
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Genotype distribution of PAI-1
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Combined carriage of TNFRII 196R variant and Beta-fibrinogen-455A
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: FXIIIA genotypes
Number of subjects: 467
Study: 15766428

Group type: EXPERIMENTAL
Intervention: Subtalar sling ankle taping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gibney ankle taping procedure
Number of subjects: 0
Study: 11914055

Group type: EXPERIMENTAL
Intervention: Intervention group (education about osteoporosis, forearm bone densitometry)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group (education about osteoporosis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 0
Study: 9809757

Group type: EXPERIMENTAL
Intervention: Low resiliency sole material
Number of subjects: 60

Group type: COMPARATOR
Intervention: High resiliency sole material
Number of subjects: 60

Group type: COMPARATOR
Intervention: All interfaces
Number of subjects: 60
Study: 7622915

Group type: EXPERIMENTAL
Intervention: Fluconazole 1200 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluconazole 1600 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluconazole 2000 mg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluconazole (all dosages)
Number of subjects: 39
Study: 2142394

Group type: EXPERIMENTAL
Intervention: 500 mg medroxyprogesterone acetate (MPA) twice weekly for 3 months
Number of subjects: 274

Group type: COMPARATOR
Intervention: Abrasio only
Number of subjects: 274
Study: 423112

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personal interview and capsule count
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 30946262

Group type: EXPERIMENTAL
Intervention: PTSR test
Number of subjects: 12

Group type: COMPARATOR
Intervention: WAnT
Number of subjects: 12
Study: 31090115

Group type: EXPERIMENTAL
Intervention: 0.05 Hz oscillatory profile
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.1 Hz oscillatory profile
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0 Hz non-oscillatory profile
Number of subjects: 14
Study: 27418573

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Comparison of ultrasound and MRI
Number of subjects: 10
Study: 25773309

Group type: EXPERIMENTAL
Intervention: Partial weight bearing beginning the same day of conservative treatment (Group 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-weight bearing after a 4-week period (Group 2)
Number of subjects: 47
Study: 23643598

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manufacturer video
Number of subjects: 40
Study: 21455611

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at low amplitude (4 mm peak to peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at high amplitude (8 mm peak to peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Number of subjects: 18
Study: 19592223

Group type: EXPERIMENTAL
Intervention: VLCD-450 (450 kcal/d)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: VLCD-800 (800 kcal/d)
Number of subjects: 132
Study: 17479256

Group type: EXPERIMENTAL
Intervention: alpha‐human ANP (0.05 microg/kg per minute)
Number of subjects: 16

Group type: COMPARATOR
Intervention: BNP (0.01 microg/kg per minute)
Number of subjects: 16
Study: 15011749

Group type: EXPERIMENTAL
Intervention: Elevated vaginal npIGFBP‐1
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Adjusted for covariates
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 473
Study: 11526473

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 217
Study: 9144047

Group type: EXPERIMENTAL
Intervention: 2% minocycline gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 7965549

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 2447664

Group type: EXPERIMENTAL
Intervention: Iloprost (ZK 36374)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31453941

Group type: EXPERIMENTAL
Intervention: High-load training (80% 1RM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-load training (30% 1RM)
Number of subjects: 25
Study: 31974557

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 36907

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 36907
Study: 30079613

Group type: EXPERIMENTAL
Intervention: Emergency endodontic treatment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: STAI‐Trait/State assessment
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: NRS scale for anxiety
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 23
Study: 28589669

Group type: EXPERIMENTAL
Intervention: Multicomponent self-management intervention (MCI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 102
Study: 25543019

Group type: EXPERIMENTAL
Intervention: Saponin containing extracts
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Soaps made with plant extracts
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Soaps made without plant extracts
Number of subjects: 23

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Saponin extract applied to Lumbriculus variegatus
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Saponin containing extracts against MCF-7 breast cancer cells
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Saponin containing extracts against HT-29 colon cancer cell lines
Number of subjects: 23
Study: 24402627

Group type: EXPERIMENTAL
Intervention: Liposomial iron
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous iron
Number of subjects: 21
Study: 20847017

Group type: COMPARATOR
Intervention: Glucosamine
Number of subjects: 3803

Group type: COMPARATOR
Intervention: Chondroitin
Number of subjects: 3803

Group type: COMPARATOR
Intervention: Combination of glucosamine and chondroitin
Number of subjects: 3803

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 3803
Study: 18768022

Group type: EXPERIMENTAL
Intervention: Toothpaste
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acidic soft drinks (lemon juice and SPRITE)
Number of subjects: 6
Study: 15913411

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12903700

Group type: EXPERIMENTAL
Intervention: Heparin flushes (10 U/mL, 1 mL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal saline flushes (1 mL)
Number of subjects: 73
Study: 10475482

Group type: EXPERIMENTAL
Intervention: Dynamic cardiomyoplasty
Number of subjects: 600
Study: 8619362

Group type: EXPERIMENTAL
Intervention: Iobitridol 250 (Xenetix 250)
Number of subjects: 70

Group type: COMPARATOR
Intervention: iohexol 240 (Omnipaque 240)
Number of subjects: 70
Study: 2015168

Group type: EXPERIMENTAL
Intervention: Pinacidil (25 mg, sustained release formulation)
Number of subjects: 6
Study: 6794086

Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP) at a dosage starting from 22.5 IU/day to 67.5 IU/day over 3 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lysine-8-vasopressin (LVP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30639574

Group type: EXPERIMENTAL
Intervention: Preventive intramuscular use of 5 mg phenylephrine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Preventive intravenous use of 100 μg phenylephrine
Number of subjects: 99

Group type: COMPARATOR
Intervention: 0.9% normal saline placebo
Number of subjects: 99
Study: 28490464

Group type: EXPERIMENTAL
Intervention: β-adrenergic antagonist (propranolol) and COX-2 inhibitor (etodolac) for 11 days, starting 5 days before surgery
Number of subjects: 38
Study: 26264470

Group type: EXPERIMENTAL
Intervention: Incremental-shuttle walk test (ISWT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Six-minute walk test (6MWT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance-shuttle walk test (ESWT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 20
Study: 23565709

Group type: EXPERIMENTAL
Intervention: KAI-1678
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 21869635

Group type: EXPERIMENTAL
Intervention: Heel-raise training (100 heel raises per day for 2 months)
Number of subjects: 26
Study: 19951210

Group type: EXPERIMENTAL
Intervention: Walking intervention (30 minutes per day, 5 days per week)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Balance exercises (11 exercises, twice per week)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Regression analysis for walking adherence
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Regression analysis for balance exercises adherence
Number of subjects: 137
Study: 17573988

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7287
Study: 15164437

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Surgery plus tamoxifen
Number of subjects: 455
Study: 11563898

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no ANH)
Number of subjects: 72
Study: 9451748

Group type: EXPERIMENTAL
Intervention: rIL-2 with chemotherapy (5-fluorouracil and leucovorin)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 17
Study: 15374271

Group type: EXPERIMENTAL
Intervention: Ipriflavone (IP) 3 x 200 mg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 84
Study: 2828820

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg/d for 5 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31676895

Group type: EXPERIMENTAL
Intervention: Surgery within 49 days
Number of subjects: 643

Group type: COMPARATOR
Intervention: Surgery after 50 days or longer
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Complete histological response (ypT0)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Presence of lymph node metastases (ypT0N1)
Number of subjects: 643
Study: 27491303

Group type: EXPERIMENTAL
Intervention: Cervical spine kinesiotherapy and posture correction exercises plus Autogenic Training (AT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Autogenic Training (AT) only
Number of subjects: 152
Study: 28984527

Group type: EXPERIMENTAL
Intervention: Maternal human milk odor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25646357

Group type: EXPERIMENTAL
Intervention: 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF)
Number of subjects: 240

Group type: COMPARATOR
Intervention: cisplatin plus fluorouracil (CF)
Number of subjects: 240
Study: 24244295

Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian Network (DBN) analysis of inflammatory mediators
Number of subjects: 49
Study: 20378921

Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (MPH‐IR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18186564

Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alpha-2a (135 microg weekly for 48 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study: 17213004

Group type: EXPERIMENTAL
Intervention: Test formulation (S‐amlodipine 5 mg p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (racemate 10 mg p.o.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study: 14498767

Group type: EXPERIMENTAL
Intervention: CPH 82 (Reumacon)
Number of subjects: 0
Study: 10958764

Group type: EXPERIMENTAL
Intervention: Delta32CCR5 heterozygous patients (d/w)
Number of subjects: 107

Group type: COMPARATOR
Intervention: CCR5 wild-type patients (w/w)
Number of subjects: 107
Study: 8643897

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy (BEAM) with autologous stem cell rescue
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOEP
Number of subjects: 0
Study: 1448312

Group type: EXPERIMENTAL
Intervention: 20 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 6 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months
Number of subjects: 111

Group type: COMPARATOR
Intervention: 2 micrograms of recombinant hepatitis B vaccine (Engerix B) at zero, 1 and 2 months (specific subgroup)
Number of subjects: 111
Study: 3882143

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg, three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide and sulpiride
Number of subjects: 0
Study: 31593541

Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 eHealth intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 27362792

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive control training (CCT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low cognitive load training (active control condition)
Number of subjects: 34
Study: 26649535

Group type: EXPERIMENTAL
Intervention: Motivational interviewing via the Internet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control (reading a book on history of hearing aids)
Number of subjects: 0
Study: 23635681

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 292
Study: 21262402

Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD, 20μg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Strontium ranelate (SrR, 2g/day)
Number of subjects: 49
Study: 19136303

Group type: EXPERIMENTAL
Intervention: Oral methotrexate 15 mg weekly for 40 weeks (7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, then 15 mg weekly for 32 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17105674

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tranexamic acid
Number of subjects: 0
Study: 15053702

Group type: EXPERIMENTAL
Intervention: Practice condition (8 days of practice passing through apertures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial estimation without practice
Number of subjects: 0
Study: 11684979

Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (CPB) at 35.5‐36.5 degrees C
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (CPB) at 28‐30 degrees C
Number of subjects: 300
Study: 9741509

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 318

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/day + colestipol 20 g/day
Number of subjects: 318

Group type: COMPARATOR
Intervention: Lovastatin 80 mg/day
Number of subjects: 318

Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 318
Study: 8000839

Group type: EXPERIMENTAL
Intervention: iomeprol-300 (300 mg I ml-1)
Number of subjects: 198

Group type: COMPARATOR
Intervention: iopromide-300 (300 mg I ml-1)
Number of subjects: 198
Study: 3404813

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Trichlormethiazide
Number of subjects: 7
Study: 31708380

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/day
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg/day
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: brexpiprazole 0.5-2 mg/day
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/day (post hoc analysis)
Number of subjects: 703
Study: 31712330

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 540

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 540
Study: 28570317

Group type: EXPERIMENTAL
Intervention: Standard of care plus nebulized epinephrine (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard of care (n = 8)
Number of subjects: 16
Study: 25928457

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with etoposide and cisplatin (BEEP) every 3 weeks for a maximum of 6 cycles
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with etoposide and cisplatin (BEEP)
Number of subjects: 8
Study: 23849306

Group type: EXPERIMENTAL
Intervention: High plasma FGF‐23 concentration (highest tertile)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Continuous variable of FGF‐23
Number of subjects: 110
Study: 20418538

Group type: EXPERIMENTAL
Intervention: Methadone (0.2 mg/kg) before surgical incision
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sufentanil infusion (0.25 μg/kg/h after a load of 0.75 μg/kg)
Number of subjects: 29
Study: 18665000

Group type: EXPERIMENTAL
Intervention: Group CBT for children
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group CBT for children plus parent training
Number of subjects: 61

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 61
Study: 16480794

Group type: EXPERIMENTAL
Intervention: TdPa formulations with inactivated poliomyelitis vaccine (IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TdPa formulations without inactivated poliomyelitis vaccine (IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouse booster model with whole cell pertussis vaccine priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouse model
Number of subjects: 0
Study: 12562658

Group type: EXPERIMENTAL
Intervention: Granisetron 2 mg p.o. on day 1, followed by dexamethasone 4 mg p.o. od for 5 days
Number of subjects: 258

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg p.o. tds combined with dexamethasone 4 mg p.o. od for 5 days
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Granisetron in the delayed phase
Number of subjects: 258

Group type: COMPARATOR
Intervention: Metoclopramide in the delayed phase
Number of subjects: 258